Emergent BioSolutions, Inc. (EBS)
| Market Cap | 1.65B |
| Revenue (ttm) | 1.76B |
| Net Income (ttm) | 157.50M |
| Shares Out | 50.24M |
| EPS (ttm) | 2.97 |
| PE Ratio | 11.04 |
| Forward PE | 14.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 783,681 |
| Open | 32.85 |
| Previous Close | 32.34 |
| Day's Range | 31.95 - 33.15 |
| 52-Week Range | 26.85 - 68.03 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 45.22 (+38.0%) |
| Earnings Date | Aug 4, 2022 |
About EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat b... [Read more...]
Financial Performance
In 2021, EBS's revenue was $1.79 billion, an increase of 15.26% compared to the previous year's $1.56 billion. Earnings were $230.90 million, a decrease of -24.32%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is 45.22, which is an increase of 38.03% from the latest price.
News
Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review
Emergent BioSolutions Inc. EBS, +7.19% said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed ...
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Appl...
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infecti...
GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immuno...
Two Pharma Companies That Will Profit From The MonkeyPox Outbreak
The monkeypox outbreak has affected 780 people since identified on May 13, 2022. Vaccines are key to curtailing the spread of Monekey Pox. Two pharma companies, Geovax Labs Inc. and Emergent Biosolution...
Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract
Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for term...
Contract manufacturer Emergent says J&J breached vaccine contract
Contract manufacturer Emergent BioSolutions Inc said on Monday U.S. drugmaker Johnson & Johnson had breached an agreement by failing to buy the minimum quantity of COVID-19 vaccines made by the company.
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following inve...
Vaccine-maker shares soar on monkeypox outbreak
CNBC's Meg Tirrell joins 'Squawk Box' to break down the companies with vaccines against monkeypox as multiple countries respond to a growing number of cases.
Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?
The monkeypox opportunity could already be baked into the prices of these stocks.
Why Emergent BioSolutions Stock Is Jumping Today
Monkeypox concerns are boosting the stock.
Emergent BioSolutions opened 15% up on Monday: here's why
Emergent BioSolutions Inc (NYSE: EBS) opened another 15% up in the stock market this morning as global cases of Monkeypox continued to rise over the weekend. How does the outbreak affect Emergent BioSol...
Why Emergent Biosolutions Stock Is Rising Today
Emergent Biosolutions Inc (NYSE: EBS) shares are trading higher Monday amid increasing monkeypox concerns. A monkeypox outbreak has been reported in at least a dozen countries.
3 Monkeypox Stocks That Soared Last Week
Fear of another viral outbreak is generating a lot of buzz around these three biotech stocks.
Two US-listed companies that could stop the Monkeypox virus spread
On Friday, May 20, the World Health Organization (WHO) stated that over 80 cases of monkeypox have been confirmed in.
6 Stocks To Watch Amid Monkeypox Outbreak
A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts. What's going on?
Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, Treatments
Monkeypox stocks SIGA, EBS and TNXP are all advancing as fears mount over monkeypox. The disease is related to smallpox.
Monkeypox Fears Drive Smallpox Antiviral Makers Higher
Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.
Why Emergent BioSciences Stock Is Soaring Today
A monkeypox outbreak could boost sales for the company's smallpox vaccine.
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First ...
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimerix, Inc. (NASDAQ: CMRX), to acquire...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live aud...
SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.
NEW YORK , May 10, 2022 /PRNewswire/ -- Weiss Law, a national shareholders' rights law firm, is investigating possible false claims, deceptive accounting and reporting practices, breaches of fiduciary d...